Omeros (OMER) opened 2026 with Q1 revenue of US$9.9 million and basic EPS of US$0.71, alongside net income from continuing operations of US$51.2 million, setting a clear earnings focused tone for the quarter. Over recent periods, the company has seen quarterly revenue move from US$0 to US$9.9 million while quarterly EPS has ranged from a loss of US$0.65 to a gain of US$1.13, giving investors a wide band of outcomes to weigh as they assess how much of the latest profit is repeatable versus tied to one off items. Margins are front and center here, with the story now hinging on how durable this level of profitability proves to be.

See our full analysis for Omeros.

With the headline numbers on the table, the next step is to set these results against the prevailing narratives around Omeros and see which stories the latest margins reinforce and which they start to challenge.

Trailing US$84 million profit includes very large one off gain

• On a trailing 12 month basis Omeros reports net income of US$84.0 million and basic EPS of US$1.25, but that period also contains a one off gain of US$251.7 million that heavily influences the headline profitability.
• Consensus narrative highlights Omeros as having turned profitable with strong reported growth, and that view sits alongside the fact that earnings over the past year were previously a loss of US$182.6 million and are now positive largely due to that one off item. Anyone leaning on the bullish story needs to separate this accounting gain from the underlying US$9.9 million of Q1 2026 revenue and US$51.2 million of net income from continuing operations.
  • This creates tension where optimism about a clean turn to profitability meets the reality that a single accounting gain is larger than the entire US$84.0 million trailing profit.
  • It also means the recent Q1 2026 profit, with basic EPS of US$0.71, carries more weight for judging ongoing performance than the boosted trailing figures alone.

P/E of 11.4x sits below peers despite US$13.28 share price

• Using the trailing EPS of US$1.25, the stock trades on a P/E of 11.4x at a share price of US$13.28, compared with 15.1x for the wider US pharmaceuticals industry and 27.1x for the stated peer group.
• Supporters argue this discount backs a bullish case that Omeros is undervalued, yet the gap between the current price of US$13.28, the analyst target of US$38.00 and the cited DCF fair value of about US$247.51 shows how sensitive any upside story is to the same earnings inputs that include the US$251.7 million one off gain.
  • The lower P/E can be read as attractive, but it is built on earnings that were a loss of US$4.8 million just one quarter earlier on a trailing basis before flipping to a profit of US$84.0 million.
  • The wide spread between price and both the analyst target and DCF fair value therefore hinges on how durable investors think this new earnings base really is.

Supporters of the optimistic case often focus on this valuation gap and the recent move into profit, and if you want to see how that story is framed in full, check out the 🐂 Omeros Bull Case

Balance sheet risks offset high growth forecasts

• Risk analysis flags negative shareholders equity and debt that is not well covered by operating cash flow, alongside recent shareholder dilution, even as models show revenue projected to grow around 48.3% per year and earnings around 37.7% per year.
• Skeptics lean on these balance sheet pressures to support a bearish narrative, arguing that reliance on financing and a single very large one off gain could weigh on future value, especially if high growth forecasts do not translate into enough cash generation to comfortably support debt and reverse the negative equity position.
  • This concern is reinforced by the shift from a trailing loss of US$182.6 million a year ago to a profit of US$84.0 million now, which depends heavily on that US$251.7 million gain rather than a long track record of cash backed earnings.
  • At the same time, the Q1 2026 revenue of US$9.9 million and net income from continuing operations of US$51.2 million provide early signs of operating progress that both bulls and bears will watch against those capital structure risks.

If you are weighing these balance sheet concerns against the growth story, it is worth seeing how the more cautious side of the market lays out its case in the 🐻 Omeros Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Omeros on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play throughout this article, the real question is how you weigh them for your own portfolio. To stress test your view against the latest red flags and potential upsides, take a closer look at the 4 key rewards and 4 important warning signs

See What Else Is Out There

Omeros relies heavily on a single very large one off gain, with negative shareholders equity and debt that current operating cash flow does not comfortably support.

If you want stocks where the balance sheet itself can reduce some of that pressure, start by checking companies in the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.